<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127478</url>
  </required_header>
  <id_info>
    <org_study_id>M01-304</org_study_id>
    <nct_id>NCT00127478</nct_id>
  </id_info>
  <brief_title>A Long Term Safety Study With Atrasentan</brief_title>
  <official_title>A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate long-term safety and tolerability of
      atrasentan 10 mg in men with hormone refractory prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Every 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Oncology-related events (OREs)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Deaths</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Study drug exposure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Karnofsky performance status</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Stratification by treatment group from prior study</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and laboratory parameters</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">166</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Adenocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrasentan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to 18 years, inclusive;

          -  Subject is currently active in an atrasentan clinical study OR has histologically or
             cytologically documented diagnosis of prostate adenocarcinoma and is considered
             hormone refractory;

          -  Karnofsky Performance Score greater than or equal to 60;

          -  Adequate hematologic function and liver function tests;

          -  No New York Heart Association (NYHA) class greater than or equal to 2.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Gordon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prostate Oncology Specialists</name>
      <address>
        <city>Marina Del Rey</city>
        <state>California</state>
        <zip>32589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Clinical Research, Inc.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Isreal Medical Center, Phillips Ambulatory Care Ceneter</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViaHealth Rochester General Hospital Center for Urology</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Urology Specialist, Division of Clinical Research</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Department of Urology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CroMedia Prime/Prime Trials Vancouver Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ken Janz MD</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>3V2CAN</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Institute of Urology</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center Royal VIctoria Hosptial</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoptial de Ranguell Service d'Urologie</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex</state>
        <zip>31043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rotterdam, Department of Urology</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leighton Hospital Urology Research Dept., Michael Heal Outpatients Dept.</name>
      <address>
        <city>Crewe</city>
        <zip>CW1 4QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2005</study_first_posted>
  <last_update_submitted>November 28, 2007</last_update_submitted>
  <last_update_submitted_qc>November 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2007</last_update_posted>
  <keyword>Hormone Refractory Prostate Cancer</keyword>
  <keyword>Adenocarcinoma of the Prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrasentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

